WayneHTsujiMD

PubMed

• 37 citations
  Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study
  Christophe Cellier, Gerd Bouma, Tom van Gils, Sherine Khater, Georgia Malamut
  The Lancet. Gastroenterology & Hepatology. 2019-12-01
• 6 citations
  Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data
  Bdm Tom, Deborah P M Symmons, Sarah Brockbank, Claudio Carini, Andrew P. Cope
  RMD Open. 2018-10-25
• 52 citations
  Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and...
  Laurence E. Cheng, Zahir Amoura, Benjamin Cheah, Falk Hiepe, Barbara A. Sullivan
  Arthritis & Rheumatology. 2018-05-25

Journal Articles

• Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus  
  Sullivan, BA, Tsuji, W, Kivitz, A, et al, Lupus Sci & Med, 1/1/2016
• Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers a...  
  Gow, JM., Tsuji, WH., Williams, GJ., et al, Arth Res Ther, 1/1/2015
• Treatment of systemic lupus erythematosus patients with the B cell-activating factor (BAFF) antagonist "peptibody" blisibimod (AMG 623): Results from randomized, doubl...  
  Stohl, W., Merrill, JT., Looney, RJ., et al (Tsuji W), Arth Res Ther, 1/1/2015
• Preclinical development of AMG 139, a human antibody specifically targeting IL-23  
  Kock, K., Pan, W. J., Gow, J. M., et al (Tsuji W), Br J Pharmacol, 1/1/2015
• Modeling the pharmacokinetic-pharmacodynamic relationship of the monoclonal antimacaque-IL-15 antibody Hu714MuXHu in cynomolgus monkeys  
  Pan, WJ., Li, H., Xiao,JJ., et al (Tsuji W), Pharmacol Res Perspect, 1/1/2015
• Homeostasis of human NK cells is not IL-15 dependent  
  Lebrec, H., M. J. Horner, K. S. Gorski, et al (Tsuji W), J Immunol, 1/1/2013
• OARSI-FDA initiative: defining the disease state of osteoarthritis  
  Lane, N. E., K. Brandt, et al (Tsuji W), Osteoarthritis Cartilage, 1/1/2011
• Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-bli...  
  Cohen, Dore, Lane, Ory, Peterfy, Sharp, van der Heijde, Zhou, Tsuji, Newmark; Denosumab Rheumatoid Arthritis Study Group, Nat Clin Pract Rheumatol, 10/2008
• Rapid and sustained improvement in health-related quality of life and utilityfor 72 weeks in patients with ankylosing spondylitis receiving etanercept  
  Boonen, Patel, Traina, Chiou, Maetzel, Tsuji, J Rheumatol, 4/2008
• Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept  
  van der Heijde, D., R. Landewe, et al (Tsuji W), Ann Rheum Dis, 1/1/2008
• Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks  
  Davis, van der Heijde, Braun, Dougados, Cush, Clegg, Inman, Kivitz, Zhou, Solinger, Tsuji, Ann Rheum Dis, 11/2005
• Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept  
  Davis, van der Heijde, Dougados, Braun Cush, Clegg, Inman, de Vries, Tsuji, J Rheumatol, 9/2005
• Magnetic Resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fus...  
  Baraliakos X, Davis J, Tsuji W, Braun J, Arthritis Rheum, 4/2005
• Join now to see all

Abstracts/Posters

• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus A...
  L. E. Cheng, Z. Amoura, B. Cheah, F. Hiepe, B. A. Sullivan, L. Zhou, G. E. Arnold, W. H. Tsuji, J. T. Merrill, J. B. Chung, EULAR, 1/1/2017
• Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 (anti-B7RP-1) in Subjects with Systemic Lupus Erythematosus: Results of a Phase 1 Multicenter, Randomized, Dou...
  Sullivan BA, Tsuji W, Kivitz A, Weisman M, Wallace DJ, Boyce M, Mackay M, Looney RJ, Cohen S, Andrew MA , Arnold GE, Boedigheimer MJ, Chiu K, Ferbas J, Green CL, Kaliy..., Lupus; 10th International Congress on SLE, 1/1/2013
• Administration of AMG 557, a Human Anti- Sequential, Rising, Multiple-dose Study.
  Sullivan B, Tsuji WH, Chindalore VL, Geppert TD, Rudinskaya A, Pardo P, Kivitz A, Neuwelt CM, Mackay M, Looney RJ, Thorne JC, Andrew M, Arnold G, Boedigheimer M, Chiu ..., Arth Rheum, 1/1/2013
• Discriminative Power of Different Combinations of Bones and Joints for Assessing Change in Rheumatoid Arthritis with MRI: Results Based on Pooled Data from Four Multis...
  Peterfy C, Countryman P, DiCarlo J, Gabrielle A, Shaw T, Anisfeld A, Tsuji W, Olech E, Gaylis N, Arthritis & Rheumatism; ACR, 1/1/2010
• The Effect of Denosumab on Metacarpal Shaft Cortical Bone Loss in Patients With Erosive Rheumatoid Arthritis
  Sharp J, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R, EULAR; Annals of the Rheumatic Diseases, 1/1/2009
• Bone mineral density improved in patients with rheumatoid arthritis treated with denosumab, with or without glucocorticoids
  Lane N, Cohen S, Dore R, Zhou L, Tsuji W, Newmark R, EULAR; Annals of the Rheumatic Diseases, 1/1/2008
• Increase in hand bone mineral density in patients with rheumatoid arthritis is associated with decreased progression of bone erosion after denosumab therapy
  Deodhar A, Dore R, Sharp J, Mandel D, Schechtman J, Shergy W, Trapp R, Ory P, Peterfy C, Feurst T, Zhou L, Tsuji W, Newmark R, EULAR; Annals of the Rheumatic Diseases, 1/1/2008
• Denosumab increases bone mineral density in patients with rheumatoid arthritis: results at 12 months
  Dore R, Hurd E, Palmer W, Shergy W, Lane N, Cohen S, Zhou L, Tsuji W, Newmark R, ECCEO, 1/1/2008
• Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
  Sharp JT, Tsuji W, Harper-Barek C, Wang H, Newmark R, Arthritis & Rheumatism; ACR, 1/1/2008
• Denosumab-mediated increase of hand bone mineral density in patients with rheumatoid arthritis is associated with decreased bone erosion
  Deodhar A, Dore R, Sharp J, Mandel D, Schechtman J, Shergy W, Trapp R, Zhou L, Tsuji W, Newmark R, Arthritis & Rheumatism; ACR, 1/1/2007
• Inhibiting RANKL with denosumab decreases progression of bone erosions in patients with rheumatoid arthritis: MRI results at 6 months
  Cohen SB, Valen P, Ritchlin C, Schechtman J, Peterfy C, van der Heijde D, Zhou L, Newmark R, Tsuji W, Annals of the Rheumatic Diseases; EULAR, 1/1/2007
• Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
  Davis JC Jr, van der Heijde D, Braun J, Dougados M, Clegg DO, Kivitz A, Fleischmann R, Inman R, Ni L, Lin S-L, Tsuji W, Annals of the Rheumatic Diseases; EULAR, 1/1/2007
• Inhibiting RANKL with denosumab increases bone mineral density in patients with rheumatoid arthritis: 6-month results from a randomized, placebo-controlled trial
  Dore R, Hurd E, Palmer W, Shergy W, Zhou L, Newmark R, Tsuji W, Annals of the Rheumatic Diseases; EULAR, 1/1/2007
• Inhibiting RANKL with denosumab reduces markers of bone and cartilage turnover in patients with rheumatoid arthritis
  Lane N, Iannini M, Atkins C, Haraoui R, Zhou L, Tsuji W, Newmark R, Annals of the Rheumatic Diseases; EULAR, 1/1/2007
• The RANKL inhibitor denosumab reduces progression of the total Sharp score and bone erosions in patients with rheumatoid arthritis: x-ray results at 12 months
  Van Der Heijde D, Cohen S, Sharp J, Ory P, Zhou L, Tsuji W, Newmark R, Annals of the Rheumatic Diseases; EULAR, 1/1/2007
• Denosumab increases bone mineral density in patients with glucocorticoid-induced osteoporosis and rheumatoid arthritis
  Lane N, Cohen S, Dore R, Zhou L, Tsuji W, Newmark R, Arthritis & Rheumatism; ACR, 1/1/2007
• Population analysis of denosumab pharmacokinetics (PK) and pharmacodynamics (PD) in patients with rheumatoid arthritis (RA)
  Peterson M, Tsuji W, Newmark R, Arthritis & Rheumatism; ACR, 1/1/2007
• Denosumab inhibits RANKL, reducing progression of the total Sharp score and bone erosions in patients with rheumatoid arthritis: 12-month x-ray results
  Van Der Heijde D,Cohen S, Sharp J, Ory P, Zhou L, Tsuji W, Newmark R, Arthritis & Rheumatism; ACR, 1/1/2007
• RANKL inhibition with denosumab decreases progression of bone erosions in patients with rheumatoid arthritis: MRI results at 6 months
  Cohen SB, Valen P, Ritchlin C, Schechtman J, Peterfy C, van der Heijde D, Zhou L, Newmark R, Tsuji W, ECCEO, 1/1/2007
• RANKL inhibition with denosumab increases bone mineral density in patients with rheumatoid arthritis
  Dore R, Hurd E, Palmer W, Shergy W, Zhou L, Newmark R, Tsuji W, ECCEO, 1/1/2007
• Assessing patient-reported outcomes of patients with psoriatic arthritis treated with etanercept
  Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF, AMCP, Fall, 1/1/2006
• Efficacy and safety of up to 9 years of etanercept (ENBREL) therapy in North American patients with early and long-standing rheumatoid arthritis
  Weinblatt M, Genovese M, Moreland L, Bathon J, Kremer J, Fleischmann R, Schiff M, Chon Y, Tsuji W, Arthritis & Rheumatism; ACR; Winter Clinical Derm, 1/1/2006
• RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis
  Lane NE, Iannini M, Atkins C, Haraoui B, Zhou L, Tsuji W, Newmark R, Arthritis & Rheumatism; ACR, 1/1/2006
• Denosumab increases bone mineral density in patients with rheumatoid arthritis
  Dore R, Hurd E, Palmer W, Shergy W, Zhou L, Newmark R, Tsuji W, Arthritis & Rheumatism; ACR, 1/1/2006
• RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results
  Cohen SB, J Schechtman, P Valen, C Ritchlin, C Peterfy, D van der Heijde, L Zhou, R Newmark, W Tsuji, Arthritis & Rheumatism; ACR, 1/1/2006
• Join now to see all

Lectures

• IL-17 and IL-23: Targets with Complex Underlying Biology 
  Univerisity of Washington, 2014 - 1/1/2014
• Th17 Cells in Rheumatic Diseases 
  Univerisity of Washington - 1/1/2010
• TNF Inhibition: A Quantum Leap in Therapy of Rheumatic Diseases 
  1/1/2009
• RANKL and Denosumab in Rheumatoid Arthritis 
  Univerisity of Washington - 1/1/2007
• The clinical development history of etanercept 
  1/1/2004
• Etanercept (Enbrel) for the Treatment of Ankylosing Spondylitis 
  1/1/2003
• Join now to see all

Other

• A randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG557 in patients with systemic lupus erythematosus and active lupus a... 
  Cheng LE, Amoura Z, Cheah B, et al (Tsuji W), Arth Rheumatol Online
  1/1/2018
• The RA-MAP Consortium: a working model for academia-industry collaboration. 
  Cope, AP, Barnes, MR, Belson, A, et al (Tsuji W), Nat Rev Rheumatol Online
  1/1/2017